Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae

Antimicrob Agents Chemother. 2008 Oct;52(10):3786-8. doi: 10.1128/AAC.00628-08. Epub 2008 Aug 11.

Abstract

In a murine model of disseminated zygomycosis, low doses of amphotericin B (0.3 mg/kg body weight/day) combined with posaconazole (40 mg/kg/day) prolonged survival and reduced tissue burden with respect to that of controls and that of both drugs administered alone. Results were similar to those obtained with amphotericin B given alone at 0.8 mg/kg/day.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amphotericin B / administration & dosage*
  • Animals
  • Antifungal Agents / administration & dosage*
  • Colony Count, Microbial
  • Disease Models, Animal
  • Drug Synergism
  • Drug Therapy, Combination
  • Humans
  • Male
  • Mice
  • Mucormycosis / drug therapy*
  • Mucormycosis / microbiology
  • Rhizopus* / classification
  • Rhizopus* / drug effects
  • Rhizopus* / isolation & purification
  • Rhizopus* / pathogenicity
  • Triazoles / administration & dosage*

Substances

  • Antifungal Agents
  • Triazoles
  • posaconazole
  • Amphotericin B